Freedom Investment Management Inc. Grows Stake in DexCom, Inc. (NASDAQ:DXCM)

Freedom Investment Management Inc. lifted its stake in DexCom, Inc. (NASDAQ:DXCM) by 10.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,035 shares of the medical device company’s stock after purchasing an additional 281 shares during the quarter. Freedom Investment Management Inc.’s holdings in DexCom were worth $203,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of DXCM. Jennison Associates LLC raised its holdings in DexCom by 1,683.2% in the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after buying an additional 6,544,102 shares during the last quarter. Westfield Capital Management Co. LP raised its holdings in DexCom by 44.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock worth $190,532,000 after acquiring an additional 876,739 shares during the last quarter. Canada Pension Plan Investment Board raised its holdings in DexCom by 189.1% in the 2nd quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock worth $75,471,000 after acquiring an additional 435,401 shares during the last quarter. Intech Investment Management LLC lifted its position in DexCom by 2,083.0% in the 3rd quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company’s stock valued at $25,967,000 after acquiring an additional 369,587 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its stake in DexCom by 16.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock valued at $276,538,000 after purchasing an additional 353,019 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the topic of a number of research analyst reports. Stifel Nicolaus upped their price target on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, August 23rd. Raymond James dropped their price target on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Robert W. Baird boosted their price objective on shares of DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, August 5th. JPMorgan Chase & Co. increased their price objective on shares of DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Finally, Sanford C. Bernstein lifted their target price on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus target price of $104.59.

Insider Buying and Selling

In related news, EVP Sadie Stern sold 4,259 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. The trade was a 0.28 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 5,431 shares of company stock worth $399,319. 0.30% of the stock is owned by corporate insiders.

DexCom Trading Down 0.1 %

Shares of DXCM stock opened at $77.99 on Monday. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The stock has a fifty day simple moving average of $71.39 and a two-hundred day simple moving average of $87.55. The firm has a market capitalization of $30.46 billion, a PE ratio of 46.70, a PEG ratio of 2.38 and a beta of 1.17. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.